NCT06598475 Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
| NCT ID | NCT06598475 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Human Papillomavirus Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 225 participants |
| Start Date | 2025-03-13 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 225 participants in total. It began in 2025-03-13 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the provider- and practice-level characteristics that influence the impact of implementation strategies guided by practice facilitation in each clinical practice, to test whether the facilitator-driven provider- and practice-level implementation strategies increase provider recommendations and Human Papilloma Virus (HPV) vaccination rates and to evaluate implementation and future sustainability of the facilitator-driven implementation strategies across nine clinical practice sites
Eligibility Criteria
Inclusion Criteria: * FQHC's with less than 60% HPV vaccine initiation rate for 11-12 year old adolescents overall at their practice sites * FQHC's that have family medicine and/or pediatric practices * a total adolescent patient population at least 50% Latino * be willing for Health Care Provider (HCP) and staff members to receive education, training, and support; complete standardized measurement, and agree to randomization. * Providers, aged 18 and over, employed at each FQHC (4 staff per practice) * Staff, aged 18 and over, employed at each FQHC (5 staff per practice) * Implementation team members (i.e., administrative designee, health care providers, immunization navigators, and other staff), aged 18 and over, employed at each FQHC (4 members per practice) * Parents (aged 18 and over) of patients ages 11-17 seeking care at each FQHC (25 per practice). Exclusion Criteria: -FQHCs that participated in the pilot study were excluded.
Contact & Investigator
Daisy Y Morales Campos, PhD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center, Houston
Frequently Asked Questions
Who can join the NCT06598475 clinical trial?
This trial is open to participants of all sexes, aged 11 Years or older, up to 17 Years, studying Human Papillomavirus Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06598475 currently recruiting?
Yes, NCT06598475 is actively recruiting participants. Contact the research team at Daisy.Y.MoralesCampos@uth.tmc.edu for enrollment information.
Where is the NCT06598475 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06598475 clinical trial?
NCT06598475 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Daisy Y Morales Campos, PhD at The University of Texas Health Science Center, Houston. The trial plans to enroll 225 participants.